Leukemia drug shows promise against rare joint tumors
NCT ID NCT01207492
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested nilotinib, a drug originally used for leukemia, in 17 patients with relapsed or metastatic pigmented villonodular synovitis (PVNS) or related giant cell tumors. The goal was to see if the drug could stop tumor growth or improve symptoms. Results focused on how long patients lived without their disease getting worse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE-TYPE GIANT CELL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
H. Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Sarcoma Oncology Center
Santa Monica, California, 90403, United States
-
Stanford University Medical Center
Stanford, California, 94305, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized maintenance therapy: a smarter way to treat advanced cancer?
- New pill shows promise for rare joint tumor in early trial
- New pill for tough tumors enters human testing
- New pill could shrink rare joint tumors without surgery
- New drug hope for rare joint tumor patients who Can't have surgery
- New drug shows promise for rare joint tumor in early trial